Xenetic Biosciences, Inc. Receives Notice of Allowance for XCART(TM) Patent
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Xenetic Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. Announces Closing of $12.5 Million Private Placement Priced at a Premium to Market
Xenetic Biosciences, Inc. Announces $12.5 Million Private Placement Priced at a Premium to Market
Xenetic Biosciences, Inc. Reports First Quarter 2021 Financial Results
Xenetic Biosciences, Inc. to Present at the Q2 Virtual Investor Summit
Xenetic Biosciences, Inc. Receives Approval to Commence Exploratory Study of XCART(TM)
Xenetic Biosciences, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results
